The EU AI Act: Implications for U.S. Health Care
The European Union’s Artificial Intelligence Act (AIA), which took effect on August 1, 2024, establishes the world’s first comprehensive legal framework for AI, with significant implications for me…
Related Articles
Our Published Papers
Elevated LDL Cholesterol with a Carbohydrate-Restricted Diet: Evidence for a “Lean Mass Hyper-Responder” Phenotype doi.org/10.1093/cdn/nzab144 November 30, 2021 Case Report: Hypercholesterolemia “L…
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation
Nature – A mutant-selective AKT inhibitor shows potential as a targeted therapy for breast cancer, enabling enhanced target engagement and avoiding the dose-limiting toxicity associated…
The Nobel Prize in Physiology or Medicine 1990
The Nobel Prize in Physiology or Medicine 1990 was awarded jointly to Joseph E. Murray and E. Donnall Thomas “for their discoveries concerning organ and…
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide – PubMed
Severe aplastic anemia (SAA) is a stem cell disorder often treated with bone marrow transplantation (BMT) to reconstitute hematopoiesis. Outcomes of related HLA-haploidentical (haplo) donors…
Use of the National Cancer Institute Community Cancer Centers Program Screening and Accrual Log to Address Cancer Clinical Trial Accrual
Use of screening logs to document enrollment barriers at the local level can facilitate development of strategies to enhance accrual.
Myeloma Paper of the Day, November 7th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, November 7th, suggested by Robert Orlowski / cancer, Carolina Schinke, Clyde Bailey, Cody Ashby, Daisy V. Alapat, David Mery, Eric
Paper: Convergent Evolution Towards CD38 Biallelic Loss Is a Recurrent Mechanism of Resistance to Anti-CD38 Antibodies in Multiple Myeloma
Program: Oral and Poster Abstracts Type: Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Resistance and Response to Anti-Myeloma Therapies Hematology…
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19
This cohort study examines the association between baseline immunosuppression and/or immunotherapy-based therapies with COVID-19 severity and cytokine storm in patients with cancer.
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Sociodemographic (age, race/ethnicity) and clinical (Eastern Cooperative Oncology Group performance status, pre-existing comorbidities, and active and progressing cancer) risk factors were associated with worse COVID-19…
